Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs In Clinical Trials

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Drug: AV1625
Clinical Trial ID: NCT00345410
Mode of action: CB1-R antagonist
Phase: Inactive
Company: Sanofi
Note: In development for multiple indications

Useful Links:

Diu Hercent Binding Profile And Functional Characterization Of AVE1625, A Novel Cannabinoid Cb1 Receptor Antagonist.Diu-Hercend A, Suc-Royer I, Gallea S, Laville M, Rouyer T, Bohme GA, Benavides JSociety of Neuroscience Abstracts, 2005, 35th: Washington


May 24, 2013
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark

See our most recent Schizophrenia Bulletin theme Webinar: Taking Stock of Glutamate in Schizophrenia, held 5 February 2013.

Check out our Schizophrenia Bulletin theme Webinar: Neurotropic Infectious Agents and Cognitive Impairment in Schizophrenia, held 13 November 2012.
Copyright © 2005- 2013 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright